Endonovo Therapeutics (ENDV) Retained Earnings (2016 - 2023)
Endonovo Therapeutics has reported Retained Earnings over the past 13 years, most recently at -$66.6 million for Q3 2023.
- Quarterly results put Retained Earnings at -$66.6 million for Q3 2023, down 7.44% from a year ago — trailing twelve months through Sep 2023 was -$66.6 million (down 7.44% YoY), and the annual figure for FY2022 was -$75.1 million, down 33.09%.
- Retained Earnings for Q3 2023 was -$66.6 million at Endonovo Therapeutics, down from -$65.9 million in the prior quarter.
- Over the last five years, Retained Earnings for ENDV hit a ceiling of -$38.0 million in Q1 2019 and a floor of -$75.1 million in Q4 2022.
- Median Retained Earnings over the past 5 years was -$56.4 million (2021), compared with a mean of -$56.5 million.
- Biggest five-year swings in Retained Earnings: plummeted 48.61% in 2019 and later decreased 0.76% in 2020.
- Endonovo Therapeutics' Retained Earnings stood at -$52.9 million in 2019, then decreased by 0.76% to -$53.3 million in 2020, then decreased by 5.82% to -$56.4 million in 2021, then crashed by 33.09% to -$75.1 million in 2022, then grew by 11.34% to -$66.6 million in 2023.
- The last three reported values for Retained Earnings were -$66.6 million (Q3 2023), -$65.9 million (Q2 2023), and -$67.9 million (Q1 2023) per Business Quant data.